Rachel Wong
YOU?
Author Swipe
View article: Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registry
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registry Open
In this study of survival outcomes, current smoking was not associated with a reduction in OS, CSS, or PFS among patients with incurable pancreatic cancer. This contrasts with the results of previous studies.
View article: Stem Cell‐Based Cancer Therapies: A Commentary on Therapeutic Promise, Health Impacts and Translational Barriers
Stem Cell‐Based Cancer Therapies: A Commentary on Therapeutic Promise, Health Impacts and Translational Barriers Open
Stem cell-based cancer therapies offer novel mechanisms for tumour targeting, immune modulation and tissue repair, with applications from haematopoietic to induced pluripotent stem cells. While showing strong therapeutic promise, their cli…
View article: Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project
Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project Open
Background: BRAFV600E-mutated metastatic colorectal cancer (mCRC) is a biologically distinct and clinically aggressive subtype associated with poor outcomes. Real-world data on this population remains limited, particularly within the Austr…
View article: Tranexamic acid does not have a dose-dependent effect on postoperative delirium after cardiac surgery – a retrospective cohort study
Tranexamic acid does not have a dose-dependent effect on postoperative delirium after cardiac surgery – a retrospective cohort study Open
Background : Postoperative delirium, regularly seen after cardiac surgery, is challenging. It has significant implications for healthcare resources and significant implications for individual patients and their families. Although the exact…
View article: Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice Open
Development of the ADDIKD guideline is funded by the NSW Government as part of the Cancer Institute NSW and received no funding from external commercial sources.
View article: Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer
Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer Open
Background Immunotherapy has emerged as a standard treatment for deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Pembrolizumab became widely available as a first‐line (1L) option in Australia following the Pharmaceuti…
View article: Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.
Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer. Open
e15569 Background: Keynote 177 was a practice changing study, with pembrolizumab versus dealers’ choice chemotherapy +/- biologic significantly improving progression free survival in patients (pts) with previously untreated deficient misma…
View article: Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis
Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis Open
Background: This study explores the potential benefits of neoadjuvant chemotherapy in borderline resectable (BR) pancreatic adenocarcinoma. Despite neoadjuvant treatment (NAT) increasingly being utilised, uncertainty remains as to the opti…
View article: Early onset metastatic colorectal cancer in Australia
Early onset metastatic colorectal cancer in Australia Open
Known prognostic variables mostly favored YP versus OP with newly diagnosed mCRC, who were also more heavily treated. Consistent with this, overall survival outcomes were improved. This data does not support that CRC in YP represent a dist…
View article: Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer
Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer Open
Predictive drug testing of patient-derived tumor organoids (PDTOs) holds promise for personalizing treatment of metastatic colorectal cancer (mCRC), but prospective data are limited to chemotherapy regimens with conflicting results. We des…
View article: Supp Figure 3 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supp Figure 3 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Fig 3. Hierarchical clustering of plasma antibody profiles after 6 weeks of study treatment, using the Spearman rank correlation method with average linkage. Patient ID (0n) at the 6-week time point (best tumour response, PFS…
View article: Data from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Data from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Purpose:To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC).Patients and Methods:This open-label phase II stud…
View article: Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Fig 1. (A) PFS in plasma VEGF-C subgroups, (B) OS in plasma Ang-2 subgroups.
View article: Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Fig 1. (A) PFS in plasma VEGF-C subgroups, (B) OS in plasma Ang-2 subgroups.
View article: Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Fig 2. Change in overall (A) and specific (B) plasma antibody titres against tumour antigens from baseline (D0) to 6 weeks of treatment (6W), n=8 patients.
View article: Supplementary Legend from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supplementary Legend from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Legend
View article: Supplementary Legend from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supplementary Legend from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Legend
View article: Supplementary Tables from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supplementary Tables from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary tables 1-3
View article: Data from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Data from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Purpose:To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC).Patients and Methods:This open-label phase II stud…
View article: Supplementary Tables from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supplementary Tables from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary tables 1-3
View article: Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Fig 2. Change in overall (A) and specific (B) plasma antibody titres against tumour antigens from baseline (D0) to 6 weeks of treatment (6W), n=8 patients.
View article: Supp Figure 3 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Supp Figure 3 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Supplementary Fig 3. Hierarchical clustering of plasma antibody profiles after 6 weeks of study treatment, using the Spearman rank correlation method with average linkage. Patient ID (0n) at the 6-week time point (best tumour response, PFS…
View article: Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities
Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities Open
Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we de…